Technology has been rapidly advancing, with digital apps showing promise in IBD management. But are they evidence based? And ...
Investor's Business Daily on MSN
IPO Stock Taps Massive Medicare Market, Soars Into Buy Range
Cancer stock BillionToOne has formed an IPO base with a buy point of 123.84. The company provides cancer diagnostic tools.
A retrospective study found a higher prevalence of several autoimmune and inflammatory conditions, in addition to skin ...
Patients with psoriasis who receive antibiotics may be more likely to discontinue their biologic therapy, a new study suggests. 1 In this French cohort study, the effect increased with multiple ...
MASLD affects more than 1 in 4 individuals with IBD and is most prevalent among adults, men, and individuals living in certain geographic regions.
Johnson & Johnson Pvt. Ltd. (JnJ) has been asked to justify key aspects of its proposed Phase III clinical trial protocol for ...
Patients with inflammatory bowel disease often have to wait a long time to find the right medicine. A new method could ...
Bacteria, viruses and fungi that colonize the body — including some that live directly on eye surfaces — can have an ...
About Palisade Bio Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation of, once daily, oral PDE4 inhibitor ...
Infliximab biosimilar CT-P13 is noninferior to originator infliximab across long-term clinical outcomes, including treatment failure and steroid dependence.
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback